• McKesson posted fiscal 2027 first-quarter revenue of USD 105.4 billion, up 8%, while GAAP diluted EPS fell 18% to USD 5.15.
• Net income attributable to shareholders dropped 22% to USD 614 million; management cited a USD 293 million redemption value adjustment tied to Medical-Surgical Solutions.
• Non-GAAP adjusted diluted EPS climbed 20% to USD 9.93, supported by operational growth in North American Pharmaceutical and Oncology & Multispecialty.
• Cash used in operations was USD 220 million, driving negative free cash flow of USD 372 million; McKesson returned USD 2.6 billion to shareholders.
• Raised full-year non-GAAP adjusted diluted EPS outlook to USD 44.20-45.00; quarterly dividend increased 15% to USD 0.94 per share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. McKesson Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000927653-26-000232), on August 05, 2026, and is solely responsible for the information contained therein.